These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 19001440

  • 1. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
    Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K.
    Mol Cancer Ther; 2008 Nov; 7(11):3575-85. PubMed ID: 19001440
    [Abstract] [Full Text] [Related]

  • 2. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD, Jeun SS.
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [Abstract] [Full Text] [Related]

  • 3. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
    Jiang M, Liu Z, Xiang Y, Ma H, Liu S, Liu Y, Zheng D.
    BMC Cancer; 2011 Feb 03; 11():54. PubMed ID: 21291526
    [Abstract] [Full Text] [Related]

  • 4. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J.
    Neurosurgery; 2009 Sep 03; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [Abstract] [Full Text] [Related]

  • 5. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
    Uzzaman M, Keller G, Germano IM.
    J Neurosurg; 2007 Apr 03; 106(4):646-51. PubMed ID: 17432717
    [Abstract] [Full Text] [Related]

  • 6. Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
    Zhitao J, Long L, Jia L, Yunchao B, Anhua W.
    Tumour Biol; 2015 Dec 03; 36(12):9621-30. PubMed ID: 26142735
    [Abstract] [Full Text] [Related]

  • 7. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
    Germano IM, Emdad L, Qadeer ZA, Binello E, Uzzaman M.
    Cancer Gene Ther; 2010 Sep 03; 17(9):664-74. PubMed ID: 20523363
    [Abstract] [Full Text] [Related]

  • 8. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
    Kim SM, Woo JS, Jeong CH, Ryu CH, Lim JY, Jeun SS.
    Cancer Res; 2012 Sep 15; 72(18):4807-17. PubMed ID: 22962275
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
    Wang Y, Huang F, Cai H, Wu Y, He G, Tan WS.
    J Cancer Res Clin Oncol; 2010 Dec 15; 136(12):1827-37. PubMed ID: 20213096
    [Abstract] [Full Text] [Related]

  • 10. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
    Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS.
    Br J Cancer; 2009 Apr 07; 100(7):1154-64. PubMed ID: 19277041
    [Abstract] [Full Text] [Related]

  • 11. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
    Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, Friedman HS, Drummond KJ, Kaye AH, Gan HK, Johns TG, Hawkins CJ.
    Br J Cancer; 2008 Jul 22; 99(2):294-304. PubMed ID: 18594532
    [Abstract] [Full Text] [Related]

  • 12. Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
    Weyhenmeyer BC, Noonan J, Würstle ML, Lincoln FA, Johnston G, Rehm M, Murphy BM.
    Oncotarget; 2016 Sep 20; 7(38):61295-61311. PubMed ID: 27494880
    [Abstract] [Full Text] [Related]

  • 13. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
    Saito R, Bringas JR, Panner A, Tamas M, Pieper RO, Berger MS, Bankiewicz KS.
    Cancer Res; 2004 Oct 01; 64(19):6858-62. PubMed ID: 15466173
    [Abstract] [Full Text] [Related]

  • 14. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.
    Kock N, Kasmieh R, Weissleder R, Shah K.
    Neoplasia; 2007 May 01; 9(5):435-42. PubMed ID: 17534449
    [Abstract] [Full Text] [Related]

  • 15. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, Chang JW, Oh W, Jeun SS.
    Stem Cells; 2010 Dec 01; 28(12):2217-28. PubMed ID: 20945331
    [Abstract] [Full Text] [Related]

  • 16. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
    Yamini B, Yu X, Pytel P, Galanopoulos N, Rawlani V, Veerapong J, Bickenbach K, Weichselbaum RR.
    Clin Cancer Res; 2007 Oct 15; 13(20):6217-23. PubMed ID: 17947489
    [Abstract] [Full Text] [Related]

  • 17. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.
    Wang Y, He L, He G, Kong Y, Liu X, Cai H, Liu X, Tan W.
    Sheng Wu Gong Cheng Xue Bao; 2010 Jun 15; 26(6):780-8. PubMed ID: 20815258
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
    Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ.
    Int J Radiat Oncol Biol Phys; 2008 Jun 01; 71(2):507-16. PubMed ID: 18474311
    [Abstract] [Full Text] [Related]

  • 19. Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma.
    Park SA, Han HR, Ahn S, Ryu CH, Jeun SS.
    Oncol Rep; 2021 Mar 01; 45(3):869-878. PubMed ID: 33469674
    [Abstract] [Full Text] [Related]

  • 20. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.
    J Neurosurg; 2013 Dec 01; 119(6):1415-23. PubMed ID: 24093630
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.